Lupin Pharma Multicare Pharmaceuticals is a branded generic company and commands a premium image with the medical profession with a good position in the Women`s health and Child Care segment.

Lupin Ltd has completed the acquisition of a majority stake in Multicare Pharmaceuticals Philippines, Inc (MC) in Philippines. MC is a branded generic company and commands a premium image with the medical profession with a good position in the Women's health and Child Care segment. MC reported revenues of Php 272 Mill for the year ending December 2008. The founder, Romeo Sy, remains with a significant equity holding and will continue as the President of the organization The Philippines market is estimated at USD 2.5 Billion and is dominated by multinational companies.

Dr. Kamal Sharma, Managing Director, Lupin Ltd said, "We are extremely excited with this entry into this emerging ASEAN market and we are pleased that Mr. Romeo Sy will continue to lead the company. With the synergies of the two companies, we are targeting to be a top league company in the near term. MC has alliances with some multinationals and we respect the same."

Multicare President, Romeo Sy said that the partnership will be of considerable benefit to Mc's position in the generics industry locally. “The equity acquisition by Lupin gives us increased access to international research and development, which will further strengthen our local position”, he said.

MC with field strength of about 140 enjoys a commendable franchise with the medical fraternity and strong distribution alliances. The dedicated Global Business Development department of Lupin will ensure continual exposure to international companies and product opportunities.

Lupin is amongst the fastest growing pharmaceutical company in India with dedicated R&D facilities and is vertically integrated with presence in many global markets. This strategic partnership will provide significant benefits for both parties. MC will gain access to Lupin's existing product pipeline and manufacturing expertise. While Lupin will gain access to the established brands and supply chains in Philippines."